BLACK DIAMOND THERAPEUTICS, INC. Investment Income, Nonoperating
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Investment Income, Nonoperating of $922.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2026-06-30 was $922.00K, a 17.53% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2026-03-31 was $1.02M, a 71.93% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2025-12-31 was $1.18M, a 109.56% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2025-09-30 was $1.16M, a 125.58% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for fiscal 2025 was $4.06M, a 86.11% increase from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for fiscal 2024 was $2.18M, a 13.41% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for fiscal 2023 was $1.92M, a 5.27% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. investment income, nonoperating for fiscal 2022 was $2.03M, a 41.37% decline from fiscal 2021.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $922.00K 10-Q · filed 2026-08-05 | $1.95M 10-Q · filed 2026-08-05 | $3.13M derived: sum of 3 quarters · filed 2026-08-05 | $4.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.02M 10-Q · filed 2026-05-07 | $2.21M derived: sum of 2 quarters · filed 2026-05-07 | $3.37M derived: sum of 3 quarters · filed 2026-05-07 | $4.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.35M derived: sum of 2 quarters · filed 2026-03-16 | $3.47M derived: sum of 3 quarters · filed 2026-08-05 | $4.06M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-06 | $2.28M derived: sum of 2 quarters · filed 2026-08-05 | $2.88M 10-Q · filed 2025-11-06 | $3.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.12M 10-Q · filed 2026-08-05 | $1.71M 10-Q · filed 2026-08-05 | $2.28M derived: sum of 3 quarters · filed 2026-08-05 | $2.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $595.00K 10-Q · filed 2026-05-07 | $1.16M derived: sum of 2 quarters · filed 2026-05-07 | $1.68M derived: sum of 3 quarters · filed 2026-05-07 | $2.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $565.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.08M derived: sum of 2 quarters · filed 2026-03-16 | $1.54M derived: sum of 3 quarters · filed 2026-03-16 | $2.18M 10-K · filed 2026-03-16 |
| 2024-09-30 | $516.00K 10-Q · filed 2025-11-06 | $980.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.62M 10-Q · filed 2025-11-06 | $1.94M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $464.00K 10-Q · filed 2025-08-07 | $1.10M 10-Q · filed 2025-08-07 | $1.43M derived: sum of 3 quarters · filed 2025-08-07 | $1.86M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $637.00K 10-Q · filed 2025-05-12 | $961.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.40M derived: sum of 3 quarters · filed 2025-05-12 | $1.94M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $763.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.30M derived: sum of 3 quarters · filed 2025-03-06 | $1.92M 10-K · filed 2025-03-06 |
| 2023-09-30 | $439.00K 10-Q · filed 2024-11-05 | $978.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.60M 10-Q · filed 2024-11-05 | $2.28M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $539.00K 10-Q · filed 2024-08-06 | $1.16M 10-Q · filed 2024-08-06 | $1.84M derived: sum of 3 quarters · filed 2024-08-06 | $2.40M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $622.00K 10-Q · filed 2024-05-09 | $1.30M derived: sum of 2 quarters · filed 2024-05-09 | $1.86M derived: sum of 3 quarters · filed 2024-05-09 | $2.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.24M derived: sum of 2 quarters · filed 2024-03-12 | $1.63M derived: sum of 3 quarters · filed 2024-03-12 | $2.03M 10-K · filed 2024-03-12 |
| 2022-09-30 | $562.00K 10-Q · filed 2023-11-06 | $948.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.35M 10-Q · filed 2023-11-06 | $1.94M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $386.00K 10-Q · filed 2023-08-11 | $792.00K 10-Q · filed 2023-08-11 | $1.38M derived: sum of 3 quarters · filed 2023-08-11 | $2.16M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $406.00K 10-Q · filed 2023-05-09 | $994.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.77M derived: sum of 3 quarters · filed 2023-05-09 | $2.72M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $588.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.36M derived: sum of 2 quarters · filed 2023-03-09 | $2.31M derived: sum of 3 quarters · filed 2023-03-09 | $3.46M 10-K · filed 2023-03-09 |
| 2021-09-30 | $776.00K 10-Q · filed 2022-11-08 | $1.72M derived: sum of 2 quarters · filed 2022-11-08 | $2.88M 10-Q · filed 2022-11-08 | $4.13M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $948.00K 10-Q · filed 2022-08-09 | $2.10M 10-Q · filed 2022-08-09 | $3.35M derived: sum of 3 quarters · filed 2022-08-09 | $4.52M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.15M 10-Q · filed 2022-05-11 | $2.41M derived: sum of 2 quarters · filed 2022-05-11 | $3.57M derived: sum of 3 quarters · filed 2022-05-11 | $4.45M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $2.42M derived: sum of 2 quarters · filed 2022-03-17 | $3.30M derived: sum of 3 quarters · filed 2022-03-17 | $4.04M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.16M 10-Q · filed 2021-11-08 | $2.04M derived: sum of 2 quarters · filed 2021-11-08 | $2.79M 10-Q · filed 2021-11-08 | $3.23M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $881.00K 10-Q · filed 2021-08-12 | $1.63M 10-Q · filed 2021-08-12 | $2.06M derived: sum of 3 quarters · filed 2021-08-12 | $2.07M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $744.00K 10-Q · filed 2021-05-07 | $1.18M derived: sum of 2 quarters · filed 2021-05-07 | $1.19M derived: sum of 3 quarters · filed 2021-05-07 | $1.19M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $441.00K derived: sum of 2 quarters · filed 2021-03-25 | $450.00K derived: sum of 3 quarters · filed 2021-03-25 | $461.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $1.00K 10-Q · filed 2020-11-10 | $10.00K derived: sum of 2 quarters · filed 2020-11-10 | $21.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $9.00K 10-Q · filed 2020-08-11 | $20.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $11.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $4.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |